• AstraZeneca won US FDA clearance for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in adults who are not candidates for PD-1/PD-L1 inhibitors.
• The TROPION-Breast02 Phase III trial showed a 5-month median overall survival gain versus chemotherapy, with a hazard ratio of 0.79.
• Regulatory reviews are ongoing under Project Orbis in Australia, Canada, Singapore, Switzerland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on May 22, 2026, and is solely responsible for the information contained therein.